Anticipated and Perceived Benefits Following Hepatitis C Treatment
Status
Conditions
Details and patient eligibility
About
The study is both qualitative and quantitative, gathering patient's perceptions of HCV treatment benefits before and after HCV treatment by administering surveys and conducting in-depth qualitative patient interviews. The study seeks to understand all anticipated and actual benefits patients perceive before and after viral eradication.
Full description
This study employs a mixed methods (qualitative and quantitative) pre-post study design utilizing in-depth qualitative interviews and patient reported outcome surveys. Pre-treatment surveys and interviews will be conducted before HCV therapy commences to understand all potential psychological, social, physical and medical consequences perceived to be related to HCV and the patients' anticipation (hope for) of improvements in these factors after viral eradication. Post-treatment surveys and interviews will occur 4 to 8 months after treatment ends to examine long-term treatment benefits, i.e., changes in HCV-related factors, such as symptoms, functioning, and health status.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age 21 or older
- English-speaking
- Any genotype
- Any treatment duration (e.g. 8, 12, or 24 weeks)
- Has been written a prescription for a sofosbuvir (SOF)-containing regimen.
Exclusion criteria
- Currently listed for liver transplant; post-liver transplant
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal